Erlotinib hydrochloride (cas 183319-69-9)

Indications: Suitable for locally advanced or metastatic non-small cell lung cancer (NSCLC) after the failure of at least one chemotherapy regimen in the past. Pharmacology: Erlotinib is a tyrosine kinase inhibitor of the epidermal growth factor receptor. Erlotinib can compete with ATP to bind the intracellular catalytic region of the epidermal growth factor receptor tyrosine kinase, inhibit phosphorylation, block and inhibit the system’s transmission of intranuclear information, and achieve the effect of preventing tumor growth, controlling cell proliferation, neovascularization, and tumor metastasis. ​Compound Information: Erlotinib Hydrochloride ​Category ​Details ​Name Erlotinib Hydrochloride ​CAS Number 183319-69-9 ​Synonyms Tarceva; OSI-774; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride ​EINECS Number 620-491-0 ​Molecular Formula C₂₂H₂₄ClN₃O₄ ​Molecular Weight 429.9 g/mol ​Chemical Properties – ​Appearance Off-white solid – ​Melting Point 223–225°C – ​Storage Temp. -20°C freezer (inert atmosphere) – ​Solubility DMSO (up to 18 mg/mL with warming) – ​Form Yellow powder – ​Color White to off-white – ​pKa 5.42 (25°C) ​InChIKey GTTBEUCJPZQMDZ-UHFFFAOYSA-N ​Key Notes: ​Analytical & Handling Guidelines: